Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Update Il y a 4 ans
Reference: NCT00180895

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL


Inclusion criteria

  • Burkitt lymphoma

Links